Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third quarter financial results. Natco Pharma Ltd. shares tanked during the ...

Natco Pharma corrected a significant 32 per cent last week. The stock declined 20 per cent on Thursday and further corrected 9 per cent on Friday, dragged by the company’s weak Q3FY25 results.

Shares of NATCO Pharma tumbled another 10% in intra-day trade on Friday, February 14, extending its slide to the sixth straight session. The stock had tumbled 20% on Thursday as well following the ...

The pharmaceutical firm’s consolidated revenue from operations fell to ₹474.8 crore in Q3 FY2025, down from ₹758.6 crore in the year-ago period, reflecting a 37.4 percent decrease in ...

Natco Pharma Ltd has received final approval from the USFDA to market Bosentan 32mg tablets. This drug, Bosentan 32mg tablets is used for the treatment of pulmonary arterial hypertension (PAH).

The company had posted a consolidated net profit of Rs 212.7 crore in the third quarter of the previous fiscal year, NATCO Pharma said in a regulatory filing. Consolidated revenue from operations in ...

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent. NATCO Pharma share price: The shares of NATCO Pharma Ltd, a constituent of BSE 500, tanked 20 per cent on Thursday ...

Generic drugmaker Natco Pharma’s consolidated net profit for the December quarter declined 37.75% to ₹132.4 crore compared to ₹212.7 crore a year earlier as revenue from formulations export ...

Natco Pharma’s consolidated net profit declined 37 per cent to ₹132 crore in the third quarter ended December 31, 2024, as against ₹212 crore in the same period last year, on account of a ...

Shares of NATCO Pharma Ltd on Thursday slumped 20 per cent after the firm reported a 37.75 per cent decline in consolidated net profit in the December quarter. The stock tanked 19.86 per cent to ...

Shares of Natco Pharma Ltd fell sharply in Thursday's trade after the company reported a 38 per cent, year-on-year (YoY), decline in its December 2024 quarter (Q3 FY25) consolidated net profit.

Natco Pharma Ltd shares continued their sharp fall in Friday's trade after the company recorded a drop in its third-quarter results. The stock plunged 10.80 per cent to hit a 52-week low of Rs 868 ...